Top 10 Biotech Stocks with Highest Upside: IBIO, GALE, PPHM, CVM, NBS, SNSS, AGEN, BPAX, CYTK, TNGN (Jan 03, 2012)
Below are the top 10 Biotech stocks with highest upside potential, based on the difference between current price and Wall Street analysts' average target price.
iBio, Inc. (AMEX:IBIO) has the 1st highest upside potential in this segment of the market. Its upside is 863.9%. Its consensus target price is $8.00 based on the average of all estimates. Galena Biopharma Inc (NASDAQ:GALE) has the 2nd highest upside potential in this segment of the market. Its upside is 859.5%. Its consensus target price is $4.50 based on the average of all estimates. Peregrine Pharmaceuticals (NASDAQ:PPHM) has the 3rd highest upside potential in this segment of the market. Its upside is 591.7%. Its consensus target price is $7.13 based on the average of all estimates. CEL-SCI Corporation (AMEX:CVM) has the 4th highest upside potential in this segment of the market. Its upside is 589.9%. Its consensus target price is $2.00 based on the average of all estimates. Neostem Inc. (AMEX:NBS) has the 5th highest upside potential in this segment of the market. Its upside is 546.9%. Its consensus target price is $3.28 based on the average of all estimates.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has the 6th highest upside potential in this segment of the market. Its upside is 476.9%. Its consensus target price is $6.75 based on the average of all estimates. Agenus Inc (NASDAQ:AGEN) has the 7th highest upside potential in this segment of the market. Its upside is 450.0%. Its consensus target price is $11.00 based on the average of all estimates. BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) has the 8th highest upside potential in this segment of the market. Its upside is 388.0%. Its consensus target price is $2.45 based on the average of all estimates. Cytokinetics, Inc. (NASDAQ:CYTK) has the 9th highest upside potential in this segment of the market. Its upside is 379.2%. Its consensus target price is $4.60 based on the average of all estimates. Tengion, Inc. (NASDAQ:TNGN) has the 10th highest upside potential in this segment of the market. Its upside is 368.1%. Its consensus target price is $2.20 based on the average of all estimates.
|